Tech Stocks Rebound, Broadcom Rating Upgraded
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Should l Buy CVS?
Source: CNBC
- Market Rebound: After a tough week, tech stocks rebounded on Friday, although Amazon pulled back post-earnings, with the S&P 500 and Nasdaq still lower for the week, indicating ongoing volatility and investor focus on the tech sector.
- Surge in Capital Expenditures: Meta's capital expenditures reached $72.22 billion for the full year 2025, with plans to invest up to $135 billion in 2026, reflecting strong demand for AI infrastructure that is expected to boost earnings and backlogs for various companies.
- Broadcom Rating Upgrade: Given the capital expenditure plans from Alphabet and Meta, Broadcom's rating has been upgraded to buy, with expectations that it will exceed earnings estimates, and the current stock pullback presents an attractive entry point, showcasing confidence in the semiconductor sector.
- Economic Data Focus: Important economic data will be released next week, including the January employment report, with economists expecting nonfarm job gains of about 70,000 and an unchanged unemployment rate of 4.4%, as the market remains sensitive to changes in the employment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVS is 96.71 USD with a low forecast of 91.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 76.330
Low
91.00
Averages
96.71
High
105.00
Current: 76.330
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Pharmacies Accept TrumpRx Discount Cards for Prescription Drugs
- Launch of TrumpRx Program: President Trump officially launched the TrumpRx program on Thursday, with CVS's network of approximately 9,000 pharmacies now accepting the discount cards, aimed at reducing prescription drug costs for consumers and enhancing market competitiveness.
- Discounted Drug Range: Initially, discounts are available for 43 drugs from five pharmaceutical companies, including AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer, which is expected to attract more consumers to utilize CVS's services.
- Convenient Access Methods: Consumers can either search for drug prices on TrumpRx.gov and complete transactions or use coupon cards at participating pharmacies, streamlining the purchasing process and enhancing user experience.
- CVS and Novo Nordisk Partnership: CVS also serves as a retail pharmacy partner for Novo Nordisk's NovoCare Pharmacy, further solidifying its position in the prescription drug market and providing patients with more options.
See More
CVS Health Earnings Outlook Analysis
- Earnings Release Date: CVS Health is set to report its latest earnings pre-market on February 10, and while market focus on its 2026 guidance may impact stock price, the company has consistently exceeded earnings expectations over the past four quarters, indicating resilience in profitability.
- Medicare Payment Impact: Following the latest Medicare Advantage payment news, CVS shares have fallen over 14%, which could negatively affect investor sentiment post-earnings, particularly regarding updates to the 2026 guidance.
- Earnings Expectation Shift: Analysts forecast CVS's non-GAAP earnings for Q4 2025 at $0.99 per share, a decline from $1.19 in Q4 2024; however, expectations for a potential earnings beat remain, which could lead to a stock rebound.
- Long-Term Growth Potential: Despite pressures from Medicare payment rates, CVS's retail pharmacy and pharmacy benefits management units generate a larger share of revenue, maintaining a positive long-term growth outlook, especially when compared to UnitedHealth's valuation, which presents a more attractive investment opportunity.
See More
CVS Health Set to Release Earnings and Guidance
- Earnings Preview: CVS Health is set to release its quarterly results on February 10, with consensus expecting non-GAAP earnings of $0.99 per share, reflecting a decline from $1.19 in Q4 2024; however, optimism remains regarding potential earnings beats.
- Medicare Policy Impact: Investors will closely monitor updates to CVS's 2026 guidance, particularly the implications of the recently proposed Medicare Advantage payment rates, especially after CVS shares fell over 14% due to this news.
- Market Reaction Expectations: Despite significant volatility following the Medicare news, analysts suggest that if CVS delivers
See More
Healthcare Sector Earnings Overview
- Earnings Progress: As of February 6, 23 healthcare companies reported earnings, bringing the sector's overall reporting progress to 38%, indicating stability in industry performance and heightened investor interest.
- Pfizer Earnings Highlight: Pfizer (PFE) posted a strong Q4 with revenue of $17.6 billion, exceeding expectations; however, its shares fell due to projected revenue contraction in 2026, reflecting market concerns about future growth.
- AbbVie Outperformance: AbbVie (ABBV) reported revenue of $16.62 billion and earnings per share of $2.71, surpassing Wall Street forecasts, driven by strong performance from its flagship product Humira, with a projected total sales growth of 9.5% for the year, boosting market confidence.
- Merck's Dismal Outlook: Merck (MERK) reported a solid Q4 with revenue of $16.4 billion and EPS of $2.04, both beating expectations; however, its 2026 outlook fell short of Wall Street estimates, leading to a decline in share price and reflecting cautious market sentiment regarding future growth.
See More
Affluent Families Concerned About Geopolitical Issues, Yet Hesitant to Invest in AI, Crypto, or Gold
Geopolitical Concerns Among Wealthy Families: A report from J.P. Morgan Private Bank reveals that 20% of wealthy single-family offices identify geopolitics as their primary concern.
International vs. U.S. Perspectives: The report highlights that 74% of non-U.S. families and 57% of U.S. families consider geopolitics to be among their top five concerns.
See More
CVS Health to Lay Off 313 Employees Amid Restructuring
- Layoff Announcement: Aetna CVS Health issued a WARN notice indicating plans to lay off 313 employees in Hartford, Connecticut, between April and July 2026, with only 17 being local residents, highlighting operational adjustments in the Small Group business segment.
- Layoff Context: This reduction is part of CVS Health's broader $2 billion cost-cutting initiative announced in 2024, aiming to streamline operations by eliminating 2,900 roles, reflecting the company's strategic response to market dynamics.
- Retail Business Contraction: In 2024, CVS Health closed 299 stores and plans to close an additional 271 in 2025, indicating a strategic shift towards reducing physical retail density in response to consumer trends favoring digital purchases.
- Market Performance Recovery: Despite the challenges of layoffs and restructuring, CVS Health's stock rose 2.8% on February 6, 2026, marking a 5% gain over the week, demonstrating market confidence in its long-term strategy.
See More
CVS Pharmacies Accept TrumpRx Discount Cards for Prescription Drugs
- Launch of TrumpRx Program: President Trump officially launched the TrumpRx program on Thursday, with CVS's network of approximately 9,000 pharmacies now accepting the discount cards, aimed at reducing prescription drug costs for consumers and enhancing market competitiveness.
- Discounted Drug Range: Initially, discounts are available for 43 drugs from five pharmaceutical companies, including AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer, which is expected to attract more consumers to utilize CVS's services.
- Convenient Access Methods: Consumers can either search for drug prices on TrumpRx.gov and complete transactions or use coupon cards at participating pharmacies, streamlining the purchasing process and enhancing user experience.
- CVS and Novo Nordisk Partnership: CVS also serves as a retail pharmacy partner for Novo Nordisk's NovoCare Pharmacy, further solidifying its position in the prescription drug market and providing patients with more options.
See More
CVS Health Earnings Outlook Analysis
- Earnings Release Date: CVS Health is set to report its latest earnings pre-market on February 10, and while market focus on its 2026 guidance may impact stock price, the company has consistently exceeded earnings expectations over the past four quarters, indicating resilience in profitability.
- Medicare Payment Impact: Following the latest Medicare Advantage payment news, CVS shares have fallen over 14%, which could negatively affect investor sentiment post-earnings, particularly regarding updates to the 2026 guidance.
- Earnings Expectation Shift: Analysts forecast CVS's non-GAAP earnings for Q4 2025 at $0.99 per share, a decline from $1.19 in Q4 2024; however, expectations for a potential earnings beat remain, which could lead to a stock rebound.
- Long-Term Growth Potential: Despite pressures from Medicare payment rates, CVS's retail pharmacy and pharmacy benefits management units generate a larger share of revenue, maintaining a positive long-term growth outlook, especially when compared to UnitedHealth's valuation, which presents a more attractive investment opportunity.
See More
CVS Health Set to Release Earnings and Guidance
- Earnings Preview: CVS Health is set to release its quarterly results on February 10, with consensus expecting non-GAAP earnings of $0.99 per share, reflecting a decline from $1.19 in Q4 2024; however, optimism remains regarding potential earnings beats.
- Medicare Policy Impact: Investors will closely monitor updates to CVS's 2026 guidance, particularly the implications of the recently proposed Medicare Advantage payment rates, especially after CVS shares fell over 14% due to this news.
- Market Reaction Expectations: Despite significant volatility following the Medicare news, analysts suggest that if CVS delivers
See More
Healthcare Sector Earnings Overview
- Earnings Progress: As of February 6, 23 healthcare companies reported earnings, bringing the sector's overall reporting progress to 38%, indicating stability in industry performance and heightened investor interest.
- Pfizer Earnings Highlight: Pfizer (PFE) posted a strong Q4 with revenue of $17.6 billion, exceeding expectations; however, its shares fell due to projected revenue contraction in 2026, reflecting market concerns about future growth.
- AbbVie Outperformance: AbbVie (ABBV) reported revenue of $16.62 billion and earnings per share of $2.71, surpassing Wall Street forecasts, driven by strong performance from its flagship product Humira, with a projected total sales growth of 9.5% for the year, boosting market confidence.
- Merck's Dismal Outlook: Merck (MERK) reported a solid Q4 with revenue of $16.4 billion and EPS of $2.04, both beating expectations; however, its 2026 outlook fell short of Wall Street estimates, leading to a decline in share price and reflecting cautious market sentiment regarding future growth.
See More
Affluent Families Concerned About Geopolitical Issues, Yet Hesitant to Invest in AI, Crypto, or Gold
Geopolitical Concerns Among Wealthy Families: A report from J.P. Morgan Private Bank reveals that 20% of wealthy single-family offices identify geopolitics as their primary concern.
International vs. U.S. Perspectives: The report highlights that 74% of non-U.S. families and 57% of U.S. families consider geopolitics to be among their top five concerns.
See More
CVS Health to Lay Off 313 Employees Amid Restructuring
- Layoff Announcement: Aetna CVS Health issued a WARN notice indicating plans to lay off 313 employees in Hartford, Connecticut, between April and July 2026, with only 17 being local residents, highlighting operational adjustments in the Small Group business segment.
- Layoff Context: This reduction is part of CVS Health's broader $2 billion cost-cutting initiative announced in 2024, aiming to streamline operations by eliminating 2,900 roles, reflecting the company's strategic response to market dynamics.
- Retail Business Contraction: In 2024, CVS Health closed 299 stores and plans to close an additional 271 in 2025, indicating a strategic shift towards reducing physical retail density in response to consumer trends favoring digital purchases.
- Market Performance Recovery: Despite the challenges of layoffs and restructuring, CVS Health's stock rose 2.8% on February 6, 2026, marking a 5% gain over the week, demonstrating market confidence in its long-term strategy.
See More
